Sunitinib in Treating Patients With Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well sunitinib works in treating patients with relapsed
multiple myeloma. Sunitinib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth and by blocking blood flow to the cancer